A Study Investigating Integrated Genomics and Patient-derived Cancer Models

Overview

About this study

The aim of this project is to characterize a landscape of DNA alterations and proteomic changes in both biopsies and resected tumors of patients which have been diagnosed with aggressive/metastatic disease to identify molecular targets for which therapeutic drugs may exist.

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients must understand and provide written informed consent prior to initiation of any study-specific procedures.
  • ≥ 18 years of age.
  • Patients must have a diagnosis of confirmed malignancy.
  • Patient is a good medical candidate for a standard of care or research biopsy or surgical procedure to obtain tissue or has tissue available for analysis that has been collected within 12 months of signing consent.

 Exclusion Criteria:

  • Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent.
  • Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use.
  • Biopsy must not be considered to be more than minimal risk to the patient.
  • Contraindications to percutaneous biopsy:
    • Significant coagulopathy that cannot be adequately corrected;
    • Severely compromised cardiopulmonary function or hemodynamic instability;
    • Lack of a safe pathway to the lesion;
    • Inability of the patient to cooperate with, or to be positioned for, the procedure.

Eligibility last updated 11/10/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Aaron Mansfield, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Aaron Mansfield M.D.

(507) 293-0569

Mansfield.Aaron@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Panagiotis Anastasiadis, Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Aaron Mansfield M.D.

(507) 293-0569

Mansfield.Aaron@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mitesh Borad, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Aaron Mansfield M.D.

(507) 293-0569

Mansfield.Aaron@mayo.edu

More information

Publications

Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions